117 related articles for article (PubMed ID: 11776204)
1. [The efficacy and safety of domestic luteinizing hormone-releasing hormone analogue and low-dose norethindrone "add-back" therapy in the treatment of endometriosis].
Zhang S; Ye G; Chen H
Zhonghua Fu Chan Ke Za Zhi; 2000 Aug; 35(8):482-5. PubMed ID: 11776204
[TBL] [Abstract][Full Text] [Related]
2. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
3. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.
Vercellini P; Pietropaolo G; De Giorgi O; Pasin R; Chiodini A; Crosignani PG
Fertil Steril; 2005 Nov; 84(5):1375-87. PubMed ID: 16275232
[TBL] [Abstract][Full Text] [Related]
4. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
5. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of endometriosis with domestic luteinizing hormone--releasing hormone analogue].
Geng L; Gu FY; Zhang LZ
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):592-4, 636. PubMed ID: 7712871
[TBL] [Abstract][Full Text] [Related]
7. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
8. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
9. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
Riis BJ; Christiansen C; Johansen JS; Jacobson J
J Clin Endocrinol Metab; 1990 Apr; 70(4):920-4. PubMed ID: 2138631
[TBL] [Abstract][Full Text] [Related]
10. [Mifepristone following conservative surgery in the treatment of endometriosis].
Jiang J; Lu J; Wu R
Zhonghua Fu Chan Ke Za Zhi; 2001 Dec; 36(12):717-20. PubMed ID: 16136889
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
[TBL] [Abstract][Full Text] [Related]
12. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report.
Surrey ES; Fournet N; Voigt B; Judd HL
Obstet Gynecol; 1993 Apr; 81(4):581-6. PubMed ID: 8459971
[TBL] [Abstract][Full Text] [Related]
14. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
15. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.
Petta CA; Ferriani RA; Abrao MS; Hassan D; Rosa E Silva JC; Podgaec S; Bahamondes L
Hum Reprod; 2005 Jul; 20(7):1993-8. PubMed ID: 15790607
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
20. [Effect of gestrinone on the lipid metabolic parameters and bone mineral density in patients with endometriosis].
Zheng P; Zhang YF; Wang JD
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):175-7. PubMed ID: 15840312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
